Aranesp Ineffective in Reducing Red blood Cell Transfusions or Fatigue

FDA MEDWATCH ALERT
Amgen notified the oncology medical community of the results of a large, multicenter, randomized, placebo-controlled study showing that Aranesp was ineffective in reducing red blood cell transfusions or fatigue in patients with cancer who have anemia that is not due to concurrent chemotherapy.

The study also showed higher mortality in patients receiving Aranesp.

Aranesp is approved for the treatment of patients with anemia caused by the chemotherapy treatment of the malignant disease and should only be used in accordance with its approved product labeling.

see also:

FDA Warning 3.9.07 FDA find increased health risks to taking Aranesp, Epogen and Procrit
FDA: studies indicate health risks for taking Aranesp, Epogen, Procrit

Kaletra Accidental Overdose in Pediatric Patient Taking Kaletra Oral Solution
Abbott Sends Letter to Doctors on Infant who Died After Taking Kaletra

2007 Health Advisories Pre-made Colistimethate May Link to Cystic Fibrosis Patient's Death
Cystic Fibrosis Patient Dies After Using Pre-Mixed Colistimethate